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Background: The management of concurrent carotid and coronary artery disease is controversial. Although single-center
observational studies have revealed acceptable outcomes of combined carotid endarterectomy (CEA) and coronary artery
bypass grafting (CABG), community-based outcomes have been substantially inferior. Recently, carotid artery stenting
(CAS) has been introduced for the management of high-risk patients with carotid stenosis, including those with severe
coronary artery disease. This study was undertaken to evaluate the nationwide trends and outcomes of CAS before CABG
vs combined CEA and CABG and to assess the risk for adverse events.
Methods: The Nationwide Inpatient Sample (NIS) was used to identify patients discharged after concurrent carotid and
coronary revascularization procedures. All patients that underwent CAS before CABG and combined CEA-CABGduring
the years 2000 to 2004 were included. The type of revascularization and major adverse events (ie, in-hospital stroke and
death rates) were determined by cross-tabulating discharge diagnostic and procedural codes. Risk stratification was
performed using the Charlson Comorbidity Index. Weighted exact Cochrane-Armitage trend test and multivariate
logistic regression were used to assess the association between types of revascularization, comorbidities, complications,
and risk-adjusted mortality.
Results: During the 5-year period, 27,084 concurrent carotid revascularizations and CABG were done. Of these, 96.7%
underwent CEA-CABG, whereas only 3.3% (887 patients) had CAS-CABG. From 2000 to 2004, the proportion of
patients undergoing CAS-CABG vs CEA-CABG did not significantly changed (P  .27). Patients undergoing CAS-
CABG had fewer major adverse events than those undergoing CEA-CABG. CAS-CABG patients had a lower incidence
of postoperative stroke (2.4% vs 3.9%), and combined stroke and death (6.9% v. 8.6%) than the combined CEA-CABG
group (P < .001), although in-hospital death rates were similar (5.2% vs 5.4%). After risk-stratification, CEA-CABG
patients had a 62% increased risk of postoperative stroke compared with patients undergoing CAS before CABG (odds
ratio [OR], 1.62; 95% confidence interval [CI], 1.1-2.5; P .02). However, no differences in the risk of combined stroke
and death were observed (OR, 1.26; 95% CI, 0.9-1.6; P  NS).
Conclusion: Although CAS may currently be performed for high-risk patients, it is still infrequently used in patients who
require concurrent carotid and coronary interventions. In the United States, patients who undergo CAS-CABG have
significantly decreased in-hospital stroke rates compared with patients undergoing CEA-CABG but similar in-hospital
mortality. CAS may provide a safer carotid revascularization option for patients who require CABG. (J Vasc Surg 2008;
48:355-61.)The management of concurrent severe carotid and
coronary artery disease is controversial. Although single-
center observational studies have revealed acceptable out-
comes of combined carotid endarterectomy (CEA) and coro-
nary artery bypass grafting (CABG),1-3 community-based
outcomes have been substantially inferior.4 Stroke re-
mains the major noncardiac complication of open cardiac
surgery, with an absolute incidence of 2%. Severe carotid
artery disease has, however, been associated with a four-
fold increased risk of perioperative stroke after CABG.2,5
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doi:10.1016/j.jvs.2008.03.031Optimal timing and sequence of treatment of patients
with combined coronary and carotid stenosis also remains
unresolved, particularly for patients who require combined
urgent reconstructions during the same hospitalization.
Systematic reviews and meta-analyses of staged or simulta-
neous CEA and CABG revealed rates of perioperative ma-
jor adverse events, such as combined stroke, myocardial
infarction (MI), and death, in the 10% to 12% range.2 No
significant differences in outcomes between staged and
simultaneous procedures were noted. Carotid revascular-
ization may, however, reduce the stroke rates in patients
with combined lesions, as suggested by reduced rates of
post-CABG stroke in patients with a prior CEA.2,6,7 To be
beneficial in reducing stroke rates, carotid revascularization
and CABG need to be performed with low cardiac and
neurologic morbidity.
Carotid stenting with cerebral embolic protection is
currently reserved primarily for high-risk patients with se-
vere carotid stenosis, including those with severe coronary
artery disease.8,9 Recent observational studies have shown
that CAS may be performed before CABG with acceptable
stroke and death rates.10-13 It is unknown to what extent
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carotid and coronary artery disease. Although one potential
advantage of CAS over CEA is a reduction in the rate of
myocardial events in patients that need CABG because it is
less invasive, the need of dual antiplatelet therapy and the
potential adverse hemodynamic depression associated with
CAS may limit its utility in patients with unstable coronary
artery disease.
This study was undertaken to evaluate the nationwide
trends and outcomes of carotid interventions performed in
patients that undergo CABG in the United States (US).
The objectives of this study were to compare the results of
CAS vs CEA performed in conjunction with CABG during
the same hospitalization and to assess the risk of stroke and
death.
METHODS
The Nationwide Inpatient Sample (NIS) from the
Healthcare Cost and Utilization Project (HCUP) was used
to identify all CAS and CEA procedures performed in
conjunction with CABG from 2000 to 2004. The NIS,
which is the largest all-payer inpatient database in the
United States,14 represents a 20% stratified sample of inpa-
tient admissions to US academic, community and acute
care hospitals nationwide and includes about 1000 hospi-
tals in 35 states (federal and prison hospitals were ex-
cluded). Typical discharge data collected include demo-
graphics, primary and 14 different secondary diagnoses,
primary and 14 different secondary procedures per patient
as identified by the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) codes,
length of stay, charges, and outcomes (Appendix, online
only). Sampling weights are provided for accurate calcula-
tions based on the complex survey design. The NIS core
inpatient files were used for data extraction and analysis.
Because NIS data are publicly available and contain no
personal identifying information, this study was exempt
from Institutional Review Board approval.
All CAS and CEA procedures performed in conjunc-
tion with CABGduring the same hospitalization during the
5-year period were identified by linking the ICD-9-CM
procedural codes for CEA and CAS and procedural codes
for CABG. The ICD-9-CM coding system has had a spe-
cific code for CAS since 2004 (00.63). Before 2004, CAS
procedures were coded using less specific procedural codes.
To identify CAS patients before 2004, the NIS database
was queried using a previously described method in which
queries for the procedural codes for angioplasty of a non-
coronary vessel (39.50) and insertion of a noncoronary
artery stent (39.90) are linked to appropriate diagnostic
codes for carotid artery stenosis.15,16
Symptomatic status of patients with carotid stenosis
was determined according to the ICD-9-CM discharge
diagnosis. Patients were classified as symptomatic if the
discharge diagnosis was “carotid artery stenosis with
stroke” or if the diagnosis codes included transient ischemic
attacks (TIA) or amaurosis fugax. Patients with a discharge
diagnosis of “carotid artery stenosis without mention ofstroke,” with no accompanying diagnoses for TIA or am-
aurosis fugax, were classified as asymptomatic.
The 15 diagnosis codes (ICD-9-CM) and the clinical
classification software (CCS; Agency for Healthcare Re-
search and Quality, Rockville, Md) coding system included
in the data, which limits and prevents overcoding,17 were
used to define comorbid medical conditions and further
used to calculate a comorbidity score based on themodified
Charlson Comorbidity Index (CCI).18 The CCI is a vali-
dated measure for use with administrative data that corre-
lates with in-hospital morbidity and mortality after surgical
procedures, including elective carotid interventions.19
Each of the indicated diagnoses is assigned a weight and
summed to provide a patient’s total score. The ability of
CCI to predict in-hospital mortality was initially assessed.
Once validated, the CCI was further used to define two
groups based on surgical risk according to comorbidities
(CCI1 indicating low-risk vs CCI2 indicating greatest
comorbidity) for analyses.
The primary outcome end point of this cross-
sectional population-based study was in-hospital stroke
and death after combined carotid and coronary revascu-
larization procedures; that is, stroke or deaths, or both,
that occur after CEA or CAS performed during the same
hospitalization as CABG. Postoperative stroke was de-
fined as an ICD-9-CM secondary diagnostic code of
“post-operative stroke (997.02).” Postoperative death
was defined as any death occurring during the same
hospitalization. Mortality data were available directly
from the data set, which are entered as “died during
hospitalization” and coded from disposition of the pa-
tient. HCUP quality control procedures are routinely
performed to confirm that data values are valid, consis-
tent, and reliable.20 Weighted analyses for predictors of
in-hospital stroke and death included demographic data,
symptomatic status, preoperative comorbidities, risk
stratification, which was based on the CCI, and hospital
characteristics.
Descriptive statistics for categoric variables are pre-
sented as relative frequencies (percentages), which were
compared with the 2 test (2 for independent groups,
two-tailed P value). Continuous variables were expressed as
medians and interquartile ranges (IQR) and compared with
nonparametric tests. In-hospital stroke and death rates
were adjusted for patient age, sex, symptomatic status, and
CCI for risk-stratification using multivariate stepwise logis-
tic regression analyses. Findings were considered statisti-
cally significant for the primary end point of in-hospital
stroke and death at P .05. Multivariate odds ratios (OR)
are reported with 95% confidence intervals (CI). Relative
frequencies of the primary outcomes were calculated for
each year. Weighted exact Cochrane-Armitage trend tests
were used to determine if there were any trends in out-
comes from 2000 to 2004. Because no significant changes
in in-hospital stroke and death rates were evident, further
statistical analyses included the whole data set using the
revised trend sampling weights necessary for analyses that
spanmultiple years to reflect increases in state participation.
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RESULTS
An estimated 27,084 concurrent carotid revasculariza-
tions and CABG were performed during the same hospital-
ization during the 5-year period, and 85.5% were elective
combined procedures. Most patients (96.7%) underwent
CEA-CABG, whereas CAS-CABG was only performed in
887 patients (3.3%). From 2001 to 2004, the proportion of
patients undergoing CAS-CABG vs CEA-CABG did not
significantly change (P .16). CAS-CABG was performed
in 2.5% of all combined procedures in 2001 and in 2.9% in
2004.
Patient characteristics and comorbidities according to
type of carotid revascularization are listed in Table I. Most
patients (96.4%) underwent treatment for asymptomatic
carotid stenosis. Among patients with symptomatic steno-
sis, 12% had TIA and 88% had stroke listed as principal or
secondary diagnoses.
Patients undergoing CAS-CABG had a significantly
greater prevalence of acute MI, hypertension, and renal
failure, whereas patients in the CEA-CABG group were
older and had a greater prevalence of diabetes mellitus
(Table I). Overall, CAS-CABG patients had a higher-
surgical-risk profile according to the CCI (48.8% with CCI
2 vs 37.9% in the CEA-CABG group; P  .001). The
percentage of octogenarians was significantly higher in the
CEA-CABG group compared with the CAS-CABG group
(14.4% vs 11.4%; P  .01). The length of stay of patients
undergoing CAS-CABG (median, 11 days; IQR, 8-15
Table I. Clinical characteristics of patients undergoing
CAS-CABG and CEA-CABG
Characteristics
CAS-CABG CEA-CABG
P(n  887) (n  26,197)
Age, median (IQR) y 69 (62-76) 72 (62-77) .001a
Female sex, % 47.2 33.0 .001b
Symptomatic carotid
stenosis, % 2.8 3.6 .24
Comorbidities, %
Hypertension 68.9 63.0 .001b
Diabetes mellitus 28.0 32.4 .005b
Chronic lung disease 28.5 26.9 .29
Acute myocardial
infarction 29.7 20.4 .001b
Congestive heart
failure 2.3 2.7 .45
Renal failure 9.7 6.3 .001b
CCI, median (IQR)
score 1 (1-3) 1 (0-2) .001a
Teaching hospital, % 70.1 60.6 .001b
Elective admission, % 42.6 52.3 .001b
CABG, coronary artery bypass grafting; CAS, carotid artery stenting; CCI,
Charlson comorbidity index;CEA, carotid endarterectomy; IQR, interquar-
tile range.
aMann-Whitney U test.
bAnalysis by 2.days) was significantly longer than that of patients under-going CEA-CABG (median, 10 days; IQR, 7-15 days; P
.002). A higher proportion of CAS-CABGprocedures were
performed in teaching hospitals (70.1% vs 60.6%) as non-
elective admissions (57.4% vs 47.7%) compared with CEA-
CABG procedures.
Patients undergoing CAS-CABG had significantly
lower rates of postoperative stroke (2.4% vs 3.9%; P .001)
and slightly lower rates of combined stroke and death (6.9%
vs 8.6%; P .1) compared with patients undergoing CEA-
CABG, although in-hospital death rates were similar (5.2%
vs 5.4%, respectively). Univariate analysis revealed that
CEA-CABG patients had a 65% increased risk of postoper-
ative stroke compared with patients undergoing CAS-
CABG (odds ratio [OR], 1.65; 95% CI, 1.1-2.6; P .02).
However, no differences in the risk of combined stroke and
death were observed (OR, 1.26; 95% CI, 0.9-1.6; PNS).
Stratified analyses according to symptomatic status and
type of carotid revascularization revealed that among 973
patients with symptomatic carotid stenosis, 96.4% under-
went CEA-CABG, and postoperative stroke occurred in
14.2%. Only 25 patients with symptomatic carotid stenosis
in this series underwent CAS-CABG, and postoperative
stroke occurred in 11 (44%). Symptomatic patients under-
going CAS-CABG, therefore, had a fivefold increased risk
of postoperative stroke compared with those undergoing
CEA-CABG (OR, 4.7; 95% CI, 2.1-10.6; P  .001).
Multivariate logistic regression analysis revealed that
patients undergoing CEA-CABG had a 66% increased risk
of postoperative stroke compared with those undergoing
CAS-CABG after adjusting for age, sex, symptomatic sta-
tus, and comorbidities (OR, 1.66; 95% CI, 1.12-2.7; P 
.015). Other independent predictors for postoperative
stroke included increasing patient age, symptomatic carotid
stenosis, and CCI (Table II). Alternative logistic regression
models revealed that octogenarians had a 25% increased
risk of postoperative stroke compared with patients aged
80 years (OR, 1.25, 95% CI, 1.06-1.5; P  .011),
whereas high-risk patients (CCI 1) had a 70% increased
risk of postoperative stroke compared with low-risk patients
(CCI 1; OR, 1.7; 95% CI, 1.5-1.94; P  .001).
Increasing patient age, female sex, acute MI, renal
failure, and elective admission were identified as indepen-
dent predictors of in-hospital mortality by stepwise logistic
regression (Table II). By separate analysis in which age was
substituted by octogenarian status in the logistic regression
model, octogenarians were found to have a threefold in-
creased risk of in-hospital mortality (OR, 2.9; 95% CI,
2.6-3.3; P  .001).
DISCUSSION
The results of this large population-based study indi-
cate that asymptomatic patients who undergo CAS-CABG
have significantly decreased stroke rates compared with
those undergoing CEA-CABG but similar in-hospital mor-
tality. US statistics also specifically demonstrate that nation-
wide, CAS is performed infrequently in patients who re-
quire concurrent treatment of carotid artery lesions and
CABG. On the basis of these stroke and death figures, we
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combined revascularization strategy in high-risk asymp-
tomatic patients who require CABG. Our findings also
indicate that further improvements are necessary to reduce
in-hospital mortality, irrespective of carotid revasculariza-
tion technique, in patients that require concurrent carotid
intervention and CABG. The role of CAS-CABG in symp-
tomatic patients remains undefined as, according to our
series, it is very rarely performed.
Several observational studies have consistently reported
that the risk of stroke associated with CABG is 2% in
patients with no significant carotid disease and 3% in pa-
tients with asymptomatic severe carotid stenosis. These
figures, however, increase to 5% in those with bilateral
carotid stenosis and to 7% to 11% in patients with carotid
occlusion2; therefore, stroke therefore remains the major
noncardiac complication after CABG.
Optimal treatment of patients with concurrent carotid
and coronary artery disease remains unresolved despite
110 publications during the last 30 years reporting results
in 9000 patients.2,5,21 Although only 40% to 50% of
strokes after CABG are ipsilateral to an existing carotid
lesion, carotid revascularization is one of the few available
options to reduce the excessive stroke and death rates in
patients with combined disease.
Systematic reviews andmeta-analyses that have assessed
perioperative outcomes of staged and simultaneous CEA
and CABG demonstrate no significant differences in out-
comes between the two strategies, albeit staged procedures
have generally been associated with lower stroke and death
rates than simultaneous ones.2 Although CEA has not
consistently reduced overall stroke and death rates in pa-
Table II. Independent predictors of postoperative stroke
and death after combined carotid interventions and
coronary bypassa
Predictor Coefficient OR 95% CI P
Postoperative stroke
CEA-CABG (vs
CAS-CABG) 0.504 1.66 1.1-2.6 .015
Age 0.021 1.02 1.01-1.03 .001
Symptomatic carotid
stenosis 1.589 4.90 4.0-5.9 .001
Charlson
comorbidity index 0.253 1.29 1.2-1.3 .001
In-hospital mortality
Age 0.061 1.06 1.1-1.2 .001
Female sex 0.817 2.26 2.0-2.5 .001
Acute myocardial
infarction 0.505 1.66 1.5-1.9 .001
Renal failure 1.128 3.09 2.6-3.6 .001
Elective admission 0.204 1.23 1.1-1.4 .001
CABG, Coronary artery bypass grafting; CEA, carotid endarterectomy;
CAS, carotid artery stenting; CI, confidence interval; OR, odds ratio.
aVariables with a value of P 0.25 in the univariate analysis and those known
to be important and possible confounding factors were entered into the
multivariate logistic regression models and selected by forward stepwise
selection for P  .05 (P  .001 for models).tients undergoing CABG, recent series demonstrate thatadding CEA to CABG as a second operative procedure
does not by itself result in an increased risk of stroke and
death.3,6 In fact, intrinsic risk factors may be responsible for
the increased morbidity and mortality of combined CEA-
CABG, as demonstrated in our study, in which several
comorbidities were identified as independent predictors of
postoperative stroke and death. Reduced rates of post-
CABG stroke rates in certain high-risk patients who also
undergo carotid interventions suggest, however, that ca-
rotid revascularization might be beneficial in reducing
stroke rates if it could be performed with low stroke andMI
rates.
CAS under cerebral protection is currently reserved in
the United States for high-risk patients, including those
with severe coronary artery disease.8,22 Recent trials and
“high-risk” registries revealed that CAS can be used in such
patients with acceptable morbidity and mortality, particu-
larly when patients are neurologically asymptomatic.22-24
Recent observational studies have also reported results of
staged CAS, followed by CABG, with low periprocedural
complication rates.10-13,25,26 In most instances in which
CAS and CEA before or concomitant with CABG have
been compared, results tend to favor CAS. A recent obser-
vational study that assessed the safety and feasibility of
staged CAS, followed by CABG, in asymptomatic patients
revealed not only low periprocedural morbidity and mor-
tality of 4.8% for death and stroke at 30 days but also
long-term durable results of 71.4% freedom from all stroke
and death at 5 years.25 Our study confirms the safety and
efficacy of staged CAS and CABG in terms of perioperative
complications among asymptomatic patients and suggests
that this approach may be a valuable, if not preferable,
alternative to CEA-CABG.
Recent randomized clinical trials failed to demonstrate
noninferiority of CAS compared with CEA among symp-
tomatic low-risk patients.27,28 Although CAS has been
associated with an increased risk of stroke in symptomatic
patients, a recent randomized trial revealed that such risk
may be disproportionately higher among symptomatic pa-
tients undergoing CAS compared with CEA.28 In our
series, CAS-CABG was associated with a fivefold increased
risk of postoperative stroke compared with CEA-CABG
among symptomatic patients. This finding, however, needs
to be interpreted with caution given the small number of
symptomatic patients undergoing CAS-CABG in this se-
ries.
One possible explanation for the increased risk of stroke
in the CAS-CABG symptomatic group may be related to
the performance of CAS and CABG during the same hos-
pitalization, which could have been performed under only
aspirin and heparin therapy. Clopidogrel is frequently
avoided under these circumstances to prevent its associated
intrinsic increased risk of bleeding in patients undergoing
CABG and is only started once mediastinal bleeding has
been excluded. Although the reported experience with this
approach is limited and has been restricted primarily to
asymptomatic patients in whom no postoperative neuro-
logic adverse events have occurred,13,29 its utility in symp-
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that when combined carotid and coronary interventions are
required in patients with symptomatic carotid stenosis, CEA-
CABG is probably a better option.
One potential advantage of CAS over CEA is related to
its theoretic reduced invasiveness, which may prevent car-
diac events in patients with significant and unstable coro-
nary artery disease. Conversely, CAS-induced hemody-
namic depression may result in worsening cardiac events.30
It is unknown to what extent CAS may result in major
adverse cardiac events in patients requiring CABG. Al-
though postprocedural MI data is not available in the NIS
data set, major postoperative cardiac complications did not
occur after either CAS-CABG or CEA-CABG and in-
hospital death rates were similar, thereby suggesting a
similar incidence of major cardiac adverse events for both
carotid revascularization techniques in patients requiring
CABG.
One of the main limitations of the current study is the
inclusion of combined CAS or CEA and CABG performed
during the same hospitalization. This occurred because
unique subject identifiers within the NIS data set prevent
the identification of multiple admissions for the same pa-
tient. It is important, however, to emphasize that patients
with such severe carotid and coronary artery disease that
require treatment during the same hospitalization consti-
tute the heart of the controversy regarding the best man-
agement of patients with combined vascular disease. In fact,
nearly all patients with combined carotid and coronary
artery stenosis have varying degrees of severity of their
vascular diseases that allow them to safely undergo carotid
interventions or CABG in different hospitalizations accord-
ing to the clinical priority. In practice, therefore, only a few
patients have such severe combined disease that a staged or
simultaneous revascularization is required.2 The current
series focuses on such patients, those with severe combined
disease who are more likely to undergo their combined
reconstructions during the same hospitalization.
Although level I evidence would be ideal to determine
the best treatment strategy for patients who require com-
bined treatment of carotid and coronary arterial disease, the
design and implementation of a multicenter randomized
clinical trial has been proven impractical and unrealistic.
The heterogeneity of patients with varying degrees of cor-
onary and carotid artery disease and the preference of
carotid intervention are the main limitations for such a trial.
In this context, available evidence should focus on the
outcomes of those patients with severe combined disease
that required simultaneous or staged urgent procedures.
Although the present study is large, recent, and based
on the entire spectrum of CAS-CABG and CEA-CABG
experience in the United States, several important limita-
tions should be acknowledged. First, miscoded andmissing
data can occur in large administrative data sets, such as the
NIS; however, HCUP quality control procedures are rou-
tinely performed to confirm that NIS data values are valid,
consistent, and reliable.20 Moreover, potential misclassifi-cations, if present, would have occurred without bias to-
ward any of the two combined procedure groups.
Second, misidentification of CAS procedures may have
occurred, because no specific ICD-9-CM procedural code
for CAS existed before 2004. Linking and pairing angio-
plasty and stenting codes with diagnostic codes for carotid
disease using primary and different levels of secondary
codes, however, did not significantly change the results,
which suggest that patients undergoing CAS-CABG were
appropriately identified.
Third, the NIS data set only includes in-hospital stroke
and death rates, which may erroneously be considered too
low when compared with the usually reported 30-day rates
of major adverse events after carotid interventions. More-
over, the inability to include as part of the primary end
point the postprocedural MI rates, which are not reported
in the NIS data set, would also suggest an apparently lower
combined major adverse event rate in this series.
Fourth, the inability to perform an intention-to-treat
analysis in patients undergoing staged procedures may bias
the results against patients undergoing simultaneous CEA-
CABG because patients who suffer a major complication or
death associated with the carotid revascularization are un-
likely to undergo subsequent CABG.
Finally, anatomic, procedural, and other patient char-
acteristics that could be explored as possible predictors of
adverse outcomes are not available in the NIS data set.
Future studies assessing their effects on the outcomes of
combined procedures as well as the influence of the severity
and stability of both carotid and coronary conditions will
probably alter the strategy and type of procedures used for
the treatment of patients requiring concurrent carotid and
coronary interventions. The effects of the degree of carotid
stenosis and the presence of bilateral critical carotid stenosis
in asymptomatic patients also needs further investigation,
because most patients undergoing combined carotid and
coronary interventions in the United States have asymp-
tomatic carotid disease.
CONCLUSIONS
CAS is still infrequently used in patients in the United
States who require concurrent carotid and coronary inter-
ventions. Patients with asymptomatic carotid stenosis un-
dergoing CAS-CABG have significantly decreased stroke
rates than those undergoing CEA-CABG but similar in-
hospital mortality. CAS may be a safer carotid revascular-
ization option for patients with asymptomatic carotid ste-
nosis requiring CABG in terms of postoperative stroke
prevention, but further improvements in in-hospital mor-
tality are necessary. Conversely, in patients with symptom-
atic carotid stenosis, CEA-CABG is probably a better op-
tion. The best treatment approach for patients requiring
combined carotid and coronary interventions is, however,
still undefined and should be established by comparing the
two strategies in the setting of a well-powered randomized
clinical trial.
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Dr Peter Lin (Houston, Tex): Dr Timaran and colleagues
from the University of Texas Southwestern Medical Center shouldwhich they analyzed the outcome of patients undergoing carotid
stenting prior to CABG vs those who underwent combined carotid
endarterectomy and CABG using a nationwide inpatient sample.
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Volume 48, Number 2 Timaran et al 361In their analysis, nearly 97% of patients underwent carotid endar-
terectomy and coronary bypass, while 3 % underwent a staged
carotid stenting prior to CABG. The authors reported that the
carotid endarterectomy and coronary bypass group had a greater
in-hospital stroke and combined stroke and death rate compared to
patients who underwent an initial carotid stenting followed by
coronary bypass. The authors concluded that carotid stenting is a
safer revascularization option compared to carotid endarterectomy
in patients requiring coronary bypass.
I have one comment and two questions for the authors. My
first comment is that while the authors should be applauded for
their effort in analyzing a population-based nationwide database,
the conclusion of this study should be viewed with caution since, in
this nationwide inpatient sample database, the status such as ca-
rotid symptoms was based on the ICD-9 discharge diagnosis,
which is subjected to potential miscoding or administrative coding
error. Additionally, important anatomical variables, such as carotid
lesion location, presence of high bifurcations, and lesion ulcer-
ations, are not included in this database. Comparative analysis
between carotid endarterectomy vs stenting without considering
these anatomical variables may result in a biased outcome. Lastly,
the outcome of study was limited to the in-hospital clinical out-
come. Longer-term data, such as 30-day treatment outcome or
follow-up information are not included in this analysis.
My first question relates to the patient groups of the study,
which included two groups. The first group included those under-
going carotid stenting, followed by staged coronary bypass, while
the second group included those who underwent a combined
carotid endarterectomy and coronary bypass. Did you consider
separating the latter group of patient into those who underwent an
initial carotid endarterectomy, followed by coronary artery bypass,
vs those who underwent a combined carotid endarterectomy and
coronary bypass? More specifically, patients who underwent a
staged carotid endarterectomy under local anesthesia prior to
coronary bypass may serve as an important control group when
comparing to patients who underwent a staged carotid stenting
prior to coronary bypass. Our group has previously reported the
outcome of patients who underwent carotid endarterectomy under
local anesthesia prior to coronary bypass, with excellent treatment
result. Since carotid stenting is typically performed under local
anesthesia, this particular patient cohort (ie, patients undergoing
carotid endarterectomy under local anesthesia) may provide a
more relevant comparative value to patients who received carotid
stenting prior to coronary bypass.
My second question is related to the anticoagulation regimen
of these patients. It is a common practice to administer clopidogrel
or Plavix [Sanofi-Aventis, Bridgewater, NJ] for at least 3 months in
patients who received carotid stenting. In many clinical practices,elective coronary bypass is delayed if a patient is on Plavix due to
the concern of mediastinal bleeding during open heart surgery.
Frequently Plavix is stopped early in order for patients to undergo
coronary bypass. Can you provide further insight from you analysis
regarding the practice pattern or preference of patients who were
given Plavix and underwent a staged coronary bypass? Was this
medication stopped prior to their heart operation, or does this
anticoagulation regimen impact on the treatment outcome?
I’d like to thank the association for the opportunity to discuss
this study, and also thank the authors for providing me with a
well-written manuscript well ahead the meeting.
Dr Carlos H. Timaran:Obviously, the NIS data set has a lot
of limitations as far as analysis of different outcomes. However, in
answer to your second question, the reason for us to explore this
data set and analyze the outcomes of combined carotid and coro-
nary revascularization has to do with clinical situations we have
faced recently in which treating patients using the standard ap-
proach (ie, CEA-CABG) was not possible. In our institution, our
cardiothoracic surgeons, for one reason or another, don’t like to do
combined procedures and they prefer us to stage them. Currently,
we prefer staged CAS prior to CABG, and thus far we have treated
several patients successfully.
We wanted, however, to know what the trends and changes in
the treatment of combined carotid and coronary artery disease
were and the outcomes nationwide. Unfortunately, in this data set,
there is no information about anticoagulation or antiplatelet ther-
apy. I can tell you what we do, based on what some studies have
suggested. We perform CAS first. We load these patients with
Plavix and maintain them on dual antiplatelet therapy for 10 days.
We then discontinue Plavix for 5 days, and then the patients
undergo CABG. We resume Plavix postoperatively once mediasti-
nal bleeding is ruled out, which happens 48 to 72 hours after
CABG. Again, this is based on suggestions from several observa-
tional studies. I have to say, that there are a few studies that have
described CAS performed with only heparin and aspirin. The
increased risk of carotid stent thrombosis makes us and others
believe that dual antiplatelet therapy is required in most cases.
Regarding your first question, the data set suggests that
among the CEA-CABG group, most patients underwent staged
CEA-CABG. Although it is not possible to determine the exact
timing of the procedures, it appears that one-quarter of the pa-
tients in that group underwent combined simultaneous CEA-
CABG. Although it may be important to separate those two
subgroups (ie, those undergoing staged vs simultaneous CEA-
CABG), we did not do it due to limitations with the data set and
because preliminary analyses did not reveal much differences. We
thus decided to lump together these patients in one group.
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diagnosis and procedural codes
ICD-9-CM Diagnosis Code ICD-9CM Procedure Code
Carotid artery occlusion and stenosis without mention of
cerebral infarction 433.1 Carotid endarterectomy 38.12
Carotid artery occlusion and stenosis with cerebral infarction 433.11 Angioplasty or atherectomy of noncoronary vessel 39.5
Multiple and bilateral carotid artery occlusion and stenosis
without mention of cerebral infarction 433.3 Endovascular repair of vessel 39.7
Multiple and bilateral carotid artery occlusion and stenosis
with cerebral infarction 433.31 Insertion of noncoronary artery stent or stents 39.9
Transient cerebral ischemia 435.9 Percutaneous insertion of carotid artery stent 0.63
Amaurosis fugax 362.34
